Abstract
Acute lymphoblastic leukemia is the most common tumor of childhood. Using of modern treatment chemotherapy regimens, we can reach about 90 % of 5-year survival. An important problem – patients with relapses of the disease, as well as children with the persistence of minimal residual disease (MRD), which is absolutely necessary in hematopoietic stem cell transplantation aspects. The possibilities of continuous intensive chemotherapy are limited by high toxicity, and therefore targeted drugs are used to achieve MRD-negative remission in children, in particular, a bispecific antibody – blinatumomab.This article presents our own experience of using blinatumomab in patients using various financial sources, the technical features of using within the federal medical center. Also, undesirable effects of the drug and their therapy are mentioned.
Highlights
Для цитирования: Батманова Н.А., Валиев Т.Т., Киргизов К.И., Варфоломеева С.Р
Using of modern treatment chemotherapy regimens, we can reach about 90 % of 5-year survival
An important problem – patients with relapses of the disease, as well as children with the persistence of minimal residual disease (MRD), which is absolutely necessary in hematopoietic stem cell transplantation aspects
Summary
Blinatumomab in acute lymphoblastic leukemia treatment: features of therapy organization, supplement issues and therapy-related toxicity. For citation: Batmanova N.A., Valiev T.T., Kirgizov K.I., Varfolomeeva S.R. Blinatumomab in acute lymphoblastic leukemia treatment: features of therapy organization, supplement issues and therapy-related toxicity. Для успешной алло-ТГСК при ОЛЛ у детей крайне важен низкий уровень минимальной остаточной болезни (МОБ) [3]. В этом случае наиболее значимый эффект для пациентов с В-линейным ОЛЛ показал препарат блинатумомаб [4]. Первый успешный опыт применения блинатумомаба у взрослых продемонстрировал эффективность в терапии пациентов с фолликулярной лимфомой, а также лимфомой из клеток зоны мантии [5]. В настоящее время блинатумомаб зарегистрирован в Российской Федерации в качестве монотерапии для лечения Ph-негативного, CD19-позитивного рецидивирующего и/или рефрактерного ОЛЛ у взрослых, и успешно применяется на базе как федеральных, так и региональных медицинских организаций. Research on the effectiveness and safety of blinatumomab: results and side effects [13]
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Russian Journal of Pediatric Hematology and Oncology
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
